Lahey Hospital & Medical Center’s Institute of Urology is committed to research and clinical trials to find better ways to prevent, diagnose and treat urologic cancers.
Prostate Cancer Research
The Lahey Institute of Urology has evaluated The OPKO Diagnostics 4Kscore™ in predicting the diagnosis of prostate cancer prior to prostate biopsy. This molecular assay may be helpful in determining the likelihood that a patient with a prior negative prostate biopsy will be diagnosed with cancer on repeat biopsy.
These molecular-based strategies in patient care are designed to benefit patients and assist urologists in selecting patients appropriately for prostate biopsy.
We also are collaborating in clinical trials of dietary supplements that hold promise in prostate cancer chemoprevention.
Bladder Cancer Research
We are currently collaborating in clinical trials of molecular-targeted therapies and dietary supplements that hold promise in the prevention of diagnosis, recurrence and/or progression of bladder cancer.
Urologic Oncology Research Laboratory
The Lahey Institute of Urology is privileged to have a Urologic Oncology Research Laboratory headed by Kimberly Rieger-Christ, PhD. Dr. Reiger-Christ is a senior scientist in the Institute of Urology and the Sophia Gordon Cancer Center at Lahey Hospital & Medical Center and holds an academic position as an Assistant Professor at Tufts University Medical School.
She joined Lahey Clinic in 1998, where she has partnered in building the research program. For the past 10 years she has overseen the urology residents’ research program and conducted the oversight of research within the urology department.
The lab allows for translational research focused on various biologic markers for bladder and prostate cancer. These efforts open the possibility of taking cutting-edge research from the laboratory to assess and evaluate prognostic markers along with therapeutics for our patients.